Karus Therapeutics presenting at BioEquity 2016

Oxford, UK, 21 April 2016 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of cancer has announced that it will be giving a company presentation at BioEquity 2016, Copenhagen, Denmark, 10-11 May 2016. Simon Kerry, Karus’s CEO, will be presenting on Wednesday, 11 May 2016 at 9:20am. For more […]

KA2237 and KA2507. Novel, oral cancer immunotherapeutics targeting PI3K-p110ß/p110δ and HDAC6 with single-agent and combination activity (New Orleans)

KA2237 and KA2507: Novel, oral cancer immunotherapeutics targeting PI3K-p110ß/p110δ and HDAC6 with single-agent and combination activity. Alexander R., Bone E.A., Cecil A.R.L., Colman L., Dow J., Finan P., Finnemore D., Gatland A., Haque K., Lensun L., Roitt S., Rogers H., Silva F.A., Ward P; Whale A., Shuttleworth S.J. In: Proceedings of the 107th Annual Meeting of […]